TNF and rheumatoid arthritis: This marked the first time in Taiwan that a tumor necrosis factor-alpha (TNF-α) inhibitor had been used to treat active RA patients with inadequate response to methotrexate (MTX)-based conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).